We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU.
Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.
Gordon Sussman, N. Chapman-Rothe, Tao Ding et al.· Clinical and Experimental Al...· 0 citations
In this post hoc analysis funded by AstraZeneca, benralizumab reduced eosinophil‐related protein biomarker expression.
Benralizumab reduced eosinophil‐derived neurotoxin concentrations, which were dose‐independent and irrespective of BHRA status.
E. Rodríguez-Suárez, M. Cardner, D. Muthas et al.· Clinical and Experimental Al...· 0 citations
Chronic spontaneous urticaria (CSU) is a heterogeneous mast cell-driven disease associated with a substantial burden on patients' quality of life. Although most patients achieve disease control with guideline-recommended therapies, a relevant proportion remains refractory, highlighting important unmet needs. This narra...
A. Giménez-Arnau, F. Barei, A. Salman· Italian journal of dermatolo...· 0 citations
Chronic urticaria is a mast cell-driven inflammatory disease characterized by recurrent wheals, angioedema or both for more than 6 weeks, with substantial effects on sleep, quality of life, mental health and daily functioning. Type I autoallergic and type IIb autoimmune mechanisms represent major endotypes, but many pa...
A. Salman, M. Al-Ahmad, M. Al-Nesf et al.· Journal of the European Acad...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.